Skip to main content
Bioventus Inc. logo

Bioventus Inc. — Investor Relations & Filings

Ticker · BVS ISIN · US09075A1088 US Manufacturing
Open in API
Filings indexed 435 across all filing types
Latest filing 2026-06-04 Declaration of Voting R…
Country US United States of America
Listing US BVS

About Bioventus Inc.

https://www.bioventus.com/

Bioventus Inc. is a global medical device company focused on developing and commercializing innovations for active healing, particularly in orthopedics. The company's operations are structured around three segments: Pain Treatments, Restorative Therapies, and Surgical Solutions. Its portfolio includes clinically differentiated, cost-efficient, and minimally invasive treatments designed to help patients resume active lives. Key products include hyaluronic acid (HA) joint pain injection therapies such as DUROLANE®, GELSYN-3®, and SUPARTZ FX®; the StimRouter® neuromodulation system for chronic peripheral nerve pain; the EXOGEN® Ultrasound Bone Healing System; and a comprehensive range of surgical orthobiologics. Bioventus aims to provide solutions that improve patient outcomes and quality of life.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is a Form 8-K filed under Item 5.07: Submission of Matters to a Vote of Security Holders, detailing the voting results at the 2026 Annual Meeting (election of directors and ratification of auditors). This matches the category for Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-06-04 English
SD
Regulatory Filings Classification · 87% confidence The document is a SEC Form SD (“Specialized Disclosure Report”) for conflict minerals, which is a specific regulatory filing rather than a full annual or interim report. It does not present comprehensive financial statements or result announcements, but rather a specialized compliance disclosure with an exhibit reference. There is no dedicated category for conflict minerals disclosures in the list, so it falls under the fallback “Regulatory Filings” (RNS).
2026-05-29 English
8-K
Regulatory Filings Classification · 9% confidence The document is a U.S. SEC Form 8-K “Current Report” disclosing a Class II reclassification by the FDA, CMS billing updates, and forward-looking statements. It does not contain financial statements or constitute an earnings release, management analysis, or other specific report, but is a general regulatory filing. Therefore it is best classified under Regulatory Filings (RNS).
2026-05-21 English
10-Q - Bioventus Inc. (0001665988) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-06 English
8-K - Bioventus Inc. (0001665988) (Filer)
Earnings Release Classification · 93% confidence The document is a Form 8-K Current Report primarily furnishing a press release (Exhibit 99.1) announcing the company’s financial results for the quarter ended March 28, 2026. This constitutes an initial announcement of quarterly financial results (key highlights only), matching the definition of an Earnings Release. Q1 2026
2026-05-06 English
ARS - Bioventus Inc. (0001665988) (Filer)
Annual Report FY 2025
2026-04-22 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.